There’s a new program at the US Food and Drug Administration. One designed to afford innovative devices a speedier review process. This Innovation Pathway 2.0 program is designed for pre-market evaluations of medical devices, expediting the process without reducing the need or quality of safety and effectiveness reviews. And some 30 years ago, there was a similar process for smaller companies- it worked, then, too. (I know, we used it- twice!)